13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-001496-11-GB
(EUCTR)
15/01/201015/03/2010The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1 Multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple Sclerosis
Trade Name: Revaxis
Product Name: Revaxis
University of NottinghamNULLNot Recruiting Female: yes
Male: yes
46 Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):United Kingdom
2EUCTR2009-011523-31-GB
(EUCTR)
23/06/200916/04/2009A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACA study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
MedDRA version: 9.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10046859;Term: Vaccination
Trade Name: Menitorix
Trade Name: Pneumovax II
Trade Name: REVAXIS
R & D, Cambridge University HospitalsNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom